Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1013-1019

  Matulonis, U A ^a   Penson, R T ^b   Domchek, S M ^c   Kaufman, B ^d   Shapira Frommer, R ^d   Audeh, M W ^e   Kaye, S ^f   Molife, L R ^f   Gelmon, K A ^g   Robertson, J D ^h   Mann, H ^h   Ho, T W ^h   Coleman, R L ⁱ  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BRCA1 2 mutation; monotherapy; olaparib; ovarian cancer; pooled analysis

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; OLAPARIB; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ARTICLE; CANCER RECURRENCE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; FALLOPIAN TUBE; FATIGUE; GERMLINE MUTATION; HEADACHE; HUMAN; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; VOMITING; ADULT; AGED; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; FEMALE; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84974803101     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw133     Document Type: Article

References (19)

1. GLOBOCAN statistics. 2012. http://globocan.iarc.fr/Pages/fact_sheets_population. aspx (21 March 2016, date last accessed).
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol 2014; 26: 521-528.
4. Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res 2014; 20: 5150-5156.
5. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374: 1371-1382.
6. Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012; 23: 2605-2612.
7. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8: 10-16.
8. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
9. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADPribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-379.
10. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
11. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
12. Mateo J, Friedlander M, Sessa C et al. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation. Eur J Cancer 2013; 49(2 suppl): abstr 801.
13. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
14. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250.
15. Liu JF, Barry WT, Birrer M et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15: 1207-1214.
16. McNeish IA, Oza AM, Coleman RL et al. Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol 2015; 33(18 suppl): abstr 5508.
17. Swisher E, Brenton J, Kaufmann S et al. Updated clinical and preliminary correlative results of ARIEL2, a phase 2 study to identify ovarian cancer patients likely to respond to rucaparib. Eur J Cancer 2014; 50(6 suppl): abstr 215.
18. Ceccaldi R, O'Connor KW, Mouw KW et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015; 75: 628-634.
19. Philpot NJ, Elebute MO, Powles R et al. Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. Br J Haematol 1996; 93: 884-887.